Concepedia

Publication | Open Access

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

60

Citations

33

References

2013

Year

Abstract

The addition of bevacizumab to FOLFOXIRI produces high rates of pathologic responses and necrosis of CLM without increasing liver toxicity.

References

YearCitations

Page 1